GlassScriptPhysician profile
Catherine W Knott
NPI 1386658763
$3,758.33
in general payments reported to CMS, 2019-2025
24 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,022 · 2022: $512 · 2023: $1,232 · 2024: $852 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,375.75 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $505.22 | 2021-2024 | Trelegy Ellipta, Arexvy, Boostrix |
| Novo Nordisk INC | $407.24 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $311.59 | 2021-2024 | |
| Lilly USA, LLC | $263.54 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.03 | 2021-2024 | Jardiance |
| Shield Therapeutics INC | $115.05 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $87.01 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $80.86 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $73.47 | 2022-2024 | Qelbree, Qelbree |
| Mylan Specialty L.P. | $70.05 | 2022-2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $53.34 | 2023-2024 | Nuedexta |
| Merck Sharp & Dohme LLC | $41.55 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $39.45 | 2023-2024 | Veozah |
| Pfizer INC. | $35.89 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.39 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $27.63 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.63 | 2022 | |
| Lundbeck LLC | $17.39 | 2021 | |
| Inari Medical, INC. | $15.15 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $14.64 | 2022 | |
| Amgen INC. | $13.65 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.45 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Knott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.